-
EP4097096
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4097096
| EP4097096 - COMPOUNDS AND USES THEREOF [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 04.11.2022 Database last updated on 24.07.2024 | |
| Former | The international publication has been made Status updated on 06.08.2021 | Most recent event Tooltip | 02.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | [2022/49] | Inventor(s) | 01 /
NETHERTON, Matthew c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | 02 /
SCHILLER, Shawn, E.R. c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | 03 /
DENG, Jing c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | 04 /
ANTHONY, Neville, John 52 Lawrence Street Northborough, MA 01532 / US | 05 /
BRUCELLE, Francois c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | 06 /
RUPPEL, Sabine, K. c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | 07 /
VOIGT, Johannes, H. c/o Foghorn Therapeutics Inc. 500 Technology Square, Suite 700 Cambridge, MA 02139 / US | [2022/49] | Representative(s) | Smith, Andrew George Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [2022/49] | Application number, filing date | 21747487.3 | 29.01.2021 | [2022/49] | WO2021US15944 | Priority number, date | US202062967565P | 29.01.2020 Original published format: US 202062967565 P | [2022/49] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2021155321 | Date: | 05.08.2021 | Language: | EN | [2021/31] | Type: | A2 Application without search report | No.: | EP4097096 | Date: | 07.12.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.08.2021 takes the place of the publication of the European patent application. | [2022/49] | Search report(s) | International search report - published on: | US | 23.09.2021 | (Supplementary) European search report - dispatched on: | EP | 29.01.2024 | Classification | IPC: | C07D417/14, C07D471/10, C07D487/10, A61P35/00, A61K31/4545, A61K31/496 | [2024/09] | CPC: |
C07D417/14 (EP,IL,KR,US);
A61K31/4545 (KR);
A61K31/496 (KR);
A61P35/00 (EP,KR);
C07D471/10 (EP,IL,KR,US);
C07D487/10 (EP,IL,KR)
|
| Former IPC [2022/49] | C07D403/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/49] | Title | German: | VERBINDUNGEN UND VERWENDUNGEN DAVON | [2022/49] | English: | COMPOUNDS AND USES THEREOF | [2022/49] | French: | COMPOSÉS ET LEURS UTILISATIONS | [2022/49] | Entry into regional phase | 29.08.2022 | National basic fee paid | 29.08.2022 | Search fee paid | 29.08.2022 | Designation fee(s) paid | 29.08.2022 | Examination fee paid | Examination procedure | 08.08.2022 | Amendment by applicant (claims and/or description) | 29.08.2022 | Examination requested [2022/49] | Fees paid | Renewal fee | 31.01.2023 | Renewal fee patent year 03 | 31.01.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [ ] - No further relevant documents disclosed | International search | [A]WO2019152437 (FOGHORN THERAPEUTICS INC [US]) [A] 1-2,9-11 * , especially: pg 52, In 11-15; pg 207, Example 91, Compound B. *; | [A] - SCHEEPSTRA et al., "Bivalent Ligands for Protein Degradation in Drug Discovery", Computational and Structural Biotechnology Journa l, (20190000), vol. 17, doi:10.1016/j.csbj.2019.01.006, pages 160 - 176, XP055729199 [A] 1-2,9-11 * , especially: abstract; pg 162, col 1, para 2. * DOI: http://dx.doi.org/10.1016/j.csbj.2019.01.006 | [A] - PubChem, (20190602), Database accession no. 213932275 [A] 1-2,9-11 * , pg 2, Fig. * | [A] - PubChem, (20190602), Database accession no. 213931336, XP055859808 [A] 1-2,9-11 * , pg 2, Fig). * |